| ESTUDIO EMPA-REG OUTCOME |
| ESTUDIO EMPA-HEART |
| Mazer CD et al., Sodium-glucose cotransporter 2 inhibitors and type 2 diabetes: clinical pearls for in-hospital initiation, in-hospital management, and postdischarge, Current Opinion in Cardiology 2020 |
| Rozado J. et al., Sodium-Glucose Cotransporter-2 Inhibitors at Discharge from Cardiology Hospitalization Department: Decoding A New Clinical Scenario. J. Clin. Med. 2020 |
| Packer M., Critical examination ofmechanisms underlying the reduction in heart failure events with SGLT2 inhibitors: identification of a molecular link between their actions to stimulate erythrocytosis and to alleviate cellular stress,Cardiovasc Research, 2021 |
| Fathi et al., SGLT2‑inhibitors; more than just glycosuria and diuresis, Heart Failure Reviews, 2020 |
